Ratio_of_polyclonal-monoclonal_prostate-specific_antigen_levels._Discrimination_of_nodal_status_in_prostate_tumors_that_produce_low_marker_levels._The_preliminary_data_we_present_in_this_report_suggest_that_the_ratio_of_polyclonal-monoclonal_serum_prostate-specific_antigen_levels_may_add_clinically_useful_information_to_that_obtained_using_serum_prostate-specific_antigen_levels_alone._We_hypothesize_that_the_diversity_of_prostate-specific_antigen_ratios_observed_in_our_data_reflects_a_diversity_in_the_antigenic_and_structural_attributes_of_prostate-specific_antigen_molecules_found_in_the_sera_of_patients_with_prostate_cancer._Further,_this_heterogeneity_of_molecules_is_a_reflection_of_the_diverse_and_altered_metabolic_state_of_human_prostate_cancer_and_appears_to_be_related_to_biologic_behavior_in_individual_patients.